Skip to content

Study to Evaluate the Efficacy of Asystems' Complete Calm Supplementation on Sleep Quality and Duration, Anxiety, and Stress

Study to Evaluate the Efficacy of Asystems' Complete Calm Supplementation on Sleep Quality and Duration, Anxiety, and Stress

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05190640
Enrollment
35
Registered
2022-01-13
Start date
2021-11-01
Completion date
2022-03-15
Last updated
2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Sleep, Stress

Brief summary

This is an open-label observational single-arm clinical trial to study the efficacy of a commercial dietary supplement and its effect on sleep quality, sleep duration, anxiety, mood, and stress.

Detailed description

It is hypothesized that the dietary supplement marketed as Asystems Complete Calm (consisting of De-Stress Gummies and Sleep Gummies) will improve subjective wellbeing in trial participants, through promoting restful sleep (looking at sleep quality and duration), and reducing stress and anxiety, while lifting up the participants' mood. A total of 35 participants will be recruited for the trial following the screening. The trial will be fully remote, a technology platform will be utilized to screen, enroll and capture study data of the participants, and all participants will take the Complete Calm Product, consisting of the De-Stress Gummies (day) and Sleep Gummies (night) for four weeks.

Interventions

DIETARY_SUPPLEMENTDe-Stress Gummies

one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies

Sponsors

Citruslabs
CollaboratorINDUSTRY
Asystem, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
24 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Male & Female between 24-45 years old * Self-reported (undiagnosed) mild to moderate sleep issues * Self-reported (undiagnosed) mild to moderate anxiety * Self-reported stressful lifestyle * Must be in good health (don't report any medical conditions asked in the screening questionnaire) * Following a stable, consistent diet regimen * Willing to maintain current dietary pattern, activity level, and stable body weight for the duration of the study, and refrain from any drastic lifestyle changes

Exclusion criteria

* Currently taking any prescription anti-depressants * Currently receiving other psychotherapeutic treatment for anxiety or depression * Severe chronic conditions including oncological conditions, psychiatric disease, or other * Diagnosed insomnia * Diagnosed anxiety or depression * Food intolerances/allergies that require an epipen * Females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Change in sleep quality [Time Frame: Baseline to 4 weeks)4 weeksSurvey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in sleep quality between baseline and study intervention period.
Change in stress and anxiety [Time Frame: Baseline to 4 weeks)4 weeksSurvey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in stress/anxiety between baseline and study intervention period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026